1. Home
  2. CANG vs BMEA Comparison

CANG vs BMEA Comparison

Compare CANG & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cango Inc.  each representing two (2)

CANG

Cango Inc. each representing two (2)

HOLD

Current Price

$0.29

Market Cap

116.5M

Sector

Technology

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.20

Market Cap

138.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CANG
BMEA
Founded
2010
2017
Country
United States
United States
Employees
96
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.5M
138.1M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
CANG
BMEA
Price
$0.29
$1.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$3.00
$9.83
AVG Volume (30 Days)
816.5K
1.1M
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.19
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$428.72
N/A
Revenue Next Year
$18.39
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$0.87
52 Week High
$5.75
$3.07

Technical Indicators

Market Signals
Indicator
CANG
BMEA
Relative Strength Index (RSI) 30.73 38.35
Support Level N/A $1.05
Resistance Level $0.50 $1.47
Average True Range (ATR) 0.05 0.10
MACD -0.01 -0.01
Stochastic Oscillator 0.93 23.68

Price Performance

Historical Comparison
CANG
BMEA

About CANG Cango Inc. each representing two (2)

Cango Inc is a Bitcoin mining company with a vision to establish an integrated, world-wide infrastructure platform capable of powering the future digital economy. The operations are divided into two reportable segments (i) Bitcoin Mining Business and (ii) International Automobile Trading Business. The Company's mining operations span over 40 sites across North America, the Middle East, South America, and East Africa. Since entering the digital asset space in November 2024, Cango has activated pilot projects in both integrated energy solutions and distributed AI computing. In parallel, Cango continues to operate an online international used car export business through its subsidiary.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: